Busulfan intravenous - Otsuka Pharmaceutical

Drug Profile

Busulfan intravenous - Otsuka Pharmaceutical

Alternative Names: Busilvex; Busulfan injection - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Orphan Medical; PDL BioPharma
  • Developer Kirin Holdings Company; Orphan Medical; Otsuka Pharmaceutical; Tzamal Pharma
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haematological malignancies
  • Phase II T cell lymphoma

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in T-cell lymphoma (Combination therapy, Second-line therapy or greater, In volunteers) in South Korea (IV) (NCT02859402)
  • 25 Jul 2016 Busulfan intravenous licensed to Grupo Biotoscana in Colombia, Chile, Ecuador and Peru
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top